
|Podcasts|July 11, 2023
Beyond Glucose Control: The Expanding Role of Incretins in Diabetes and Obesity Management
Listen
0:00 / 0:00
In this MEDcast episode, Diana Isaacs, PharmD, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Dr Juan Frias to explore the mechanism of GLP-1 and GIP agonists in diabetes and weight management and examine key findings from clinical trials for the latest GLP-1/GIP dual agonist.
Advertisement
1:00 Effect of incretins on blood glucose and body weight
3:24 Evolution of GLP-1 agonists
7:45 Mechanism of tirzepatide- dual GLP-1/GIP agonist
10:35 Overview of SURPASS and SURMOUNT trials for tirzepatide
17:45 Benefits vs. risks of GLP-1 agonists
21:45 Sustainability of weight loss with incretin-based therapies
25:30 Future of metabolic diseases management
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
5


























































